Contrasting Maravai LifeSciences (NASDAQ:MRVI) & Parallax Health Sciences (OTCMKTS:PRLX)

Maravai LifeSciences (NASDAQ:MRVI) and Parallax Health Sciences (OTCMKTS:PRLX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Valuation & Earnings

This table compares Maravai LifeSciences and Parallax Health Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$208.78 million	10.46	-$130.77 million	($0.52)	-16.17
Parallax Health Sciences	N/A	N/A	N/A	N/A	N/A

Parallax Health Sciences has lower revenue, but higher earnings than Maravai LifeSciences.

Profitability

This table compares Maravai LifeSciences and Parallax Health Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Parallax Health Sciences	N/A	N/A	N/A

Institutional & Insider Ownership

50.2% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Maravai LifeSciences and Parallax Health Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2	0	2	0	2.00
Parallax Health Sciences	0	0	0	0	0.00

Maravai LifeSciences presently has a consensus price target of $6.25, indicating a potential downside of 25.67%. Given Parallax Health Sciences’ higher probable upside, analysts clearly believe Parallax Health Sciences is more favorable than Maravai LifeSciences.

Summary

Maravai LifeSciences beats Parallax Health Sciences on 5 of the 9 factors compared between the two stocks.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

About Parallax Health Sciences

Parallax Health Sciences, Inc. is an integrated digital healthcare company. It is engaged in the provision of personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. The firm operates through the following segments: Remote Patient Monitoring, Behavioral Health Systems, and Corporate. The Remote Patient Monitoring segment offers a technology platform that includes a complete remote patient care delivery system through PHM. The Behavioral Health Systems segment includes the intellectual property, Reliable Evidence-Based Outcomes Optimization Technologies, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc. The Corporate segment consists of management and administrative services. The company was founded on July 6, 2005 and is headquartered in Los Angeles, CA.